Lanreotide

FDA approved

Lanreotide (Somatuline Depot) is a long-acting somatostatin analog approved by the FDA in 2007 for acromegaly, and later for gastroenteropancreatic neuroendocrine tumors and carcinoid syndrome. It is given as a monthly injection.

At a glance

Where it acts: Hormones & metabolism
Regulatory status: FDA approvedApproved by the U.S. FDA for at least one medical use.

Mechanism of Action

Lanreotide is a cyclic octapeptide that mimics somatostatin, binding mainly somatostatin receptors 2 and 5. This suppresses release of growth hormone, IGF-1 and gut hormones, and slows the growth of some neuroendocrine tumors.

Typical Dosage (Research)

Prescription-only medicine. Dosing is set by a physician according to the FDA-approved label and the condition being treated.

Side Effects & Risks

Diarrhea, abdominal pain, nausea, injection site reactions and gallstones.

Gallstone formation, changes in blood sugar control, slow heart rate, and reduced thyroid function.

Who Uses Lanreotide

Adults with acromegaly, GEP-NETs or carcinoid syndrome.